Cargando…
Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy
PURPOSE: We assessed prognostic factors of local control and progression-free survival (PFS) of patients treated for AJCC stages T1 and T2 cervical cancer using utero-vaginal brachytherapy after chemoradiotherapy. MATERIAL AND METHODS: This retrospective single-institution analysis included patients...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034732/ https://www.ncbi.nlm.nih.gov/pubmed/36970434 http://dx.doi.org/10.5114/jcb.2023.124936 |
_version_ | 1784911271153369088 |
---|---|
author | Faivre, Jean-Christophe Jung, Paul Salleron, Julia Baumard, Florian Courrech, Florent Marchal, Frédéric Peiffert, Didier Renard, Sophie Charra-Brunaud, Claire |
author_facet | Faivre, Jean-Christophe Jung, Paul Salleron, Julia Baumard, Florian Courrech, Florent Marchal, Frédéric Peiffert, Didier Renard, Sophie Charra-Brunaud, Claire |
author_sort | Faivre, Jean-Christophe |
collection | PubMed |
description | PURPOSE: We assessed prognostic factors of local control and progression-free survival (PFS) of patients treated for AJCC stages T1 and T2 cervical cancer using utero-vaginal brachytherapy after chemoradiotherapy. MATERIAL AND METHODS: This retrospective single-institution analysis included patients who underwent brachytherapy after radiochemotherapy between 2005 and 2015 at the Institut de Cancérologie de Lorraine. Adjuvant hysterectomy was optional. A multivariate analysis of prognostic factors was carried out. RESULTS: Of 218 patients, 81 (37.2%) were AJCC stage T1, and 137 (62.8%) were AJCC stage T2. 167 (76.6%) patients had squamous cell carcinoma, 97 (44.5%) patients had pelvic nodal disease, and 30 (13.8%) patients had para-aortic nodal disease. One hundred eighty-four patients (84.4%) underwent concomitant chemotherapy, while adjuvant surgery was performed in 91 patients (41.9%) and 42 (46.2%) patients had pathological complete response. Median follow-up was 4.2 years, and local control was reported in 87.8% (95% CI: 83.0-91.8) and 87.2% (95% CI: 82.3-91.3) of patients at 2 and 5 years, respectively. In multivariate analysis, T stage (hazard ratio [HR] = 3.65, 95% CI: 1.27-10.46, p = 0.016) was associated with local control. PFS was reported in 67.6% (95% CI: 60.9-73.4) and 57.4% (95% CI: 49.3-64.2) of patients at 2 and 5 years, respectively. In multivariate analysis, para-aortic nodal disease (HR = 2.03, 95% CI: 1.16-3.54, p = 0.012), pathological complete response (HR = 0.33, 95% CI: 0.15-0.73, p = 0.006), and intermediate-risk clinical tumor volume of > 60 cc (HR = 1.90, 95% CI: 1.22-2.98, p = 0.005) were associated with PFS. CONCLUSIONS: Lower dose brachytherapy may benefit AJCC stages T1 and T2 tumors, whereas higher doses are required for larger tumors and para-aortic nodal disease involvement, respectively. Pathological complete response should be associated with better local control and not surgery. |
format | Online Article Text |
id | pubmed-10034732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-100347322023-03-24 Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy Faivre, Jean-Christophe Jung, Paul Salleron, Julia Baumard, Florian Courrech, Florent Marchal, Frédéric Peiffert, Didier Renard, Sophie Charra-Brunaud, Claire J Contemp Brachytherapy Original Paper PURPOSE: We assessed prognostic factors of local control and progression-free survival (PFS) of patients treated for AJCC stages T1 and T2 cervical cancer using utero-vaginal brachytherapy after chemoradiotherapy. MATERIAL AND METHODS: This retrospective single-institution analysis included patients who underwent brachytherapy after radiochemotherapy between 2005 and 2015 at the Institut de Cancérologie de Lorraine. Adjuvant hysterectomy was optional. A multivariate analysis of prognostic factors was carried out. RESULTS: Of 218 patients, 81 (37.2%) were AJCC stage T1, and 137 (62.8%) were AJCC stage T2. 167 (76.6%) patients had squamous cell carcinoma, 97 (44.5%) patients had pelvic nodal disease, and 30 (13.8%) patients had para-aortic nodal disease. One hundred eighty-four patients (84.4%) underwent concomitant chemotherapy, while adjuvant surgery was performed in 91 patients (41.9%) and 42 (46.2%) patients had pathological complete response. Median follow-up was 4.2 years, and local control was reported in 87.8% (95% CI: 83.0-91.8) and 87.2% (95% CI: 82.3-91.3) of patients at 2 and 5 years, respectively. In multivariate analysis, T stage (hazard ratio [HR] = 3.65, 95% CI: 1.27-10.46, p = 0.016) was associated with local control. PFS was reported in 67.6% (95% CI: 60.9-73.4) and 57.4% (95% CI: 49.3-64.2) of patients at 2 and 5 years, respectively. In multivariate analysis, para-aortic nodal disease (HR = 2.03, 95% CI: 1.16-3.54, p = 0.012), pathological complete response (HR = 0.33, 95% CI: 0.15-0.73, p = 0.006), and intermediate-risk clinical tumor volume of > 60 cc (HR = 1.90, 95% CI: 1.22-2.98, p = 0.005) were associated with PFS. CONCLUSIONS: Lower dose brachytherapy may benefit AJCC stages T1 and T2 tumors, whereas higher doses are required for larger tumors and para-aortic nodal disease involvement, respectively. Pathological complete response should be associated with better local control and not surgery. Termedia Publishing House 2023-02-09 2023-02 /pmc/articles/PMC10034732/ /pubmed/36970434 http://dx.doi.org/10.5114/jcb.2023.124936 Text en Copyright © 2023 Termedia https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) ) |
spellingShingle | Original Paper Faivre, Jean-Christophe Jung, Paul Salleron, Julia Baumard, Florian Courrech, Florent Marchal, Frédéric Peiffert, Didier Renard, Sophie Charra-Brunaud, Claire Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy |
title | Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy |
title_full | Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy |
title_fullStr | Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy |
title_full_unstemmed | Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy |
title_short | Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy |
title_sort | prognostic factors of local control and progression-free survival in ajcc stages t1 and t2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034732/ https://www.ncbi.nlm.nih.gov/pubmed/36970434 http://dx.doi.org/10.5114/jcb.2023.124936 |
work_keys_str_mv | AT faivrejeanchristophe prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy AT jungpaul prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy AT salleronjulia prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy AT baumardflorian prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy AT courrechflorent prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy AT marchalfrederic prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy AT peiffertdidier prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy AT renardsophie prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy AT charrabrunaudclaire prognosticfactorsoflocalcontrolandprogressionfreesurvivalinajccstagest1andt2cervicalcancerpatientstreatedwithadjuvantbrachytherapyafterchemoradiotherapy |